Ikena Oncology, Inc. – Trademark Portfolio

Entity Type: 03

Ikena Oncology, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include IKENA and IKENA ONCOLOGY. The owner is based in Boston, MA.

645 Summer Street, Suite 101

Boston, MA 02210

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Ikena Oncology, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Ikena Oncology, Inc. have?

Ikena Oncology, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned.

What trademark classes does Ikena Oncology, Inc. file in?

Ikena Oncology, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Ikena Oncology, Inc.'s most well-known trademarks?

Ikena Oncology, Inc.'s registered trademark portfolio includes well-known marks such as IKENA and IKENA ONCOLOGY. These are among 2 currently registered trademarks in the portfolio.

What is Ikena Oncology, Inc.'s trademark registration success rate?

Ikena Oncology, Inc. has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.